R
Rose Lab
Biotechnological solutions for aesthetic and medical applications
About Rose Lab
Founded in May 2016, Rose Lab Inc. is a South Korean company specializing in the research and development of biotechnological products for the beauty and medical sectors. The company's CEO, a plastic surgeon with 25 years of experience, established Rose Lab to create safe and effective solutions for a broader audience, merging medicine, life sciences, and polymer chemistry.
Rose Lab focuses on developing and manufacturing biostimulators and tissue-restoring materials from polymer compounds designed to promote collagen production and improve skin aging. Its core offerings include anti-aging technologies and facial fillers for the temporary improvement of facial wrinkles. The company operates on a business-to-business (B2B) model, supplying its products to beauty clinics, dermatology practices, and other healthcare providers, primarily in South Korea and other Asian markets. Revenue is generated through partnerships and supply agreements with these establishments. In early 2026, Rose Lab launched a new cosmetic product line called 'Pozelan H', based on its liquid PCL material design technology, signaling an expansion into skincare products.
Since its inception, Rose Lab has achieved significant milestones, including establishing a corporate research institute and obtaining a medical device manufacturing license in 2016. The company has received numerous certifications, including ISO 13485, ISO 9001, and GMP for its medical device manufacturing and quality management. It has also been selected for various government support programs, such as the TIPS (Tech Incubator Program for Startup) and a Post-TIPS project from the Ministry of SMEs and Startups. Rose Lab has registered several patents for its technologies, including a tissue restoration composition and a biodegradable polymer microneedle patch. The company has successfully raised KRW 10 billion in a recent funding round from Reverent Partners and Shinhan Capital to support its growth strategy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Dermatology, Advanced Materials, Longevity, biomanufacturing, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2025 | $16M | $65M | Undisclosed | ↗ |
| OtherOther financing | Mar 2021 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Rose Lab is 250 monthly website visits, up 38.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Daedeok Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rose Lab on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rose Lab’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.